(Q33375742)

26 July 2017

title

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis (English)

1 reference

26 July 2017

1 reference

1 reference

Peter P Michielsen

6

0 references

Robert Flisiak

object named as

Robert Flisiak

7

0 references

Bettina Hansen

object named as

Bettina E Hansen

2

0 references

Maria Buti

3

object named as

Maria Buti

1 reference

26 July 2017

Erik H C J Buster

1

1 reference

26 July 2017

Jean Delwaide

4

1 reference

26 July 2017

Claus Niederau

5

1 reference

26 July 2017

Pieter E Zondervan

8

1 reference

26 July 2017

Solko W Schalm

9

1 reference

26 July 2017

Harry L A Janssen

10

1 reference

26 July 2017

HBV 99-01 Study Group

11

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

26 July 2017

1 reference

26 July 2017

volume

46

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

388-394

1 reference

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

26 July 2017

cites work

1 reference

21 January 2018

1 reference

7 January 2021

Immunopathogenesis of hepatitis B.

1 reference

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

7 January 2021

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

1 reference

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

7 January 2021

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

7 January 2021

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

1 reference

7 January 2021

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy

1 reference

7 January 2021

Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays

1 reference

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

7 January 2021

The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.

1 reference

7 January 2021

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype

1 reference

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

7 January 2021

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

7 January 2021

Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep)

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21723

1 reference

26 July 2017

1 reference